Synthesis and pharmacological characterization of the selective GluK1 radioligand (S)-2-amino-3-(6-[3H]-2,4-dioxo-3,4-dihydrothieno.3,2-d] pyrimidin1(2H)- yl) propanoic acid ([3H]-NF608)

Alcaide, Anna; Marconi, Laura; Marek, Ales; Haym, Isabell; Nielsen, Birgitte; Møllerud, Stine; Jensen, Mikael; Conti, Paola; Pickering, Darryl S.; Bunch, Lennart

Published in:
MedChemComm

Link to article, DOI:
10.1039/c6md00339g

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Alcaide, A., Marconi, L., Marek, A., Haym, I., Nielsen, B., Møllerud, S., ... Bunch, L. (2016). Synthesis and pharmacological characterization of the selective GluK1 radioligand (S)-2-amino-3-(6-[3H]-2,4-dioxo-3,4-dihydrothieno.3,2-d] pyrimidin1(2H)- yl) propanoic acid ([3H]-NF608). MedChemComm, 7(11), 2136-2144. https://doi.org/10.1039/c6md00339g
Synthesis and pharmacological characterization of the selective GluK1 radioligand (S)-2-amino-3-(6-
$^{[3]}$H)-2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)propanoic acid ($^{[3]}$H-NF608)$^\dagger\ddagger$

Anna Alcaide,$^a$ Laura Marconi,$^a$$^d$ Ales Marek,$^b$ Isabell Haym,$^a$ Birgitte Nielsen,$^a$
Stine Møllerud,$^a$ Mikael Jensen,$^c$ Paola Conti,$^d$
Darryl S. Pickering$^a$ and Lennart Bunch$^a$$^*$$^a$

The kainic acid receptors belong to the class of ionotropic glutamate receptors and comprise five subunits
named GluK1–5. Radioligands are essential tools for use in binding assays aimed at ligand–receptor
structure–activity–relationship studies. Previous work has led to the synthesis of GluK1 radioligands $^{[3]}$H-
SYM2081, $^{[3]}$H–UBP310 and $^{[3]}$H–ATPA, however all strategies were work-intensive and thus not attractive.
Herein, we report the synthesis of $^{[3]}$H–NF608 and subsequent pharmacological evaluation at homomeric
recombinant rat GluK1 receptors. Binding affinities of a series of standard GluK1 ligands were shown to be
in line with previously reported affinities obtained by use of already reported radioligands.

Results and discussion

Synthesis

Firstly, we pursued a direct bromination of commercially
available UBP310 to obtain the dibromothiophene precursor
previously reported for the synthesis of $^{[3]}$H–UBP310 (Scheme
S1, ESI$^a$).$^3$ However, bromination took place at the uracil ring
only, and all attempts failed to following incorporate deute-

We next turned to investigate the high affinity, selective
GluK1 ligand NF608 (Fig. 1) which also comprises a thio-
phone ring. Its synthesis is described in only two steps from
commercially available thieno[3,2-d]pyrimidine-2,4(1H,3H)-
dione (1) (Scheme 1).\(^7\) Firstly, we attempted bromination of the thiophene ring of 3 under standard conditions (Br\(_2\) in AcOH or TFA, rt to 90 °C) (Scheme 1). However, none of the corresponding bromo or dibromo derivatives comprised by general structure 4 were observed but only the expected cleavage of the BOC group.

We therefore revised the strategy to introduce the bromine functionality earlier in the synthesis (Scheme 1), and indeed we were able to brominate the thiophene ring of 1 in the 7 position to give 5. Disappointingly, alkylation at \(N^1\) with lactone 2 (ref. 12) as the electrophile was unproductive (NaH, DMF, –65 to 80 °C) presumably due to the bulkiness of the bromine atom (Scheme 1). For that reason, we turned to pursue bromination of the 6 position of the thiopyrimidine ring in order to allow for following alkylation at \(N^1\).

The synthesis of key bromo intermediate 13 (Scheme 2) commenced with \(N^3\)-protection of commercially available methyl 3-aminothiophene-2-carboxylate (7) with trichloroacetyl isocyanate in THF to afford compound 8 in 93% yields.\(^13\) Subsequent bromination with \(Br_2\) in acetic acid at 80 °C successfully provided exclusively 5-bromo-thiophene 9, which was then treated with 2 M ammonia in methanol to afford urea 10.\(^13\) Cyclization with potassium tert-butoxide in DMF, furnished the desired heterocyclic product 11.\(^13\) Alkylation at \(N^1\) with lactone 2\(^12\) was performed using sodium hydride as base in DMF, as described in a similar procedure.\(^7\) The alkylation product 12 was obtained in only 18% – a yield which could likely be optimized. Cleavage of the BOC group in the presence of 2 M aq HCl provided key bromo amino acid intermediate 13, in overall 6 steps. Deuteration over Pd/C in a basic aqueous media gave 80% deuterium incorporation, furnishing deuterated product [\(D_6\)]-NF608 together with NF608, in overall 57% yield.

\section*{Tritiation}

Having established the method for deuterium incorporation, tritiation was carried out by use of \(T_2\) (gas) with Pd/C as catalyst in water to give [\(\text{[H]}\)]-NF608 in high yield (Scheme 3) at a specific activity of 16.3 Ci mmol\(^{-1}\).

\section*{Radiochemical stability}

Formulation of [\(\text{[H]}\)]-NF608 was chosen as a 1 mCi mL\(^{-1}\) solution in \(H_2O\)-EtOH (1:1) and the radiochemical stability was monitored over time. When stored at –21 °C, the stability was determined to be 98% after 42 days and 97.5% after 90 days. When stored at –196 °C for 90 days, no decomposition could be detected.

\section*{GluK1 binding pharmacology}

\subsection*{Assay validation}

Based upon our previous publication we anticipated [\(\text{[H]}\)]-NF608 to be a high affinity radioligand at GluK1 since unlabeled NF608 had shown a \(K_i\) of 5.3 nM.\(^7\) Initial tests indicated high level of specific binding of the radiolabel to homomeric rat GluK1 expressed in \textit{sf9} cell membranes and subsequently an assay validation was conducted using 1 mM (S)-glutamate to define nonspecific binding. No specific binding was seen using uninfected \textit{sf9} cell membranes. A series of buffers, temperatures, pH conditions and washing protocols were evaluated (Table 1) and 50 mM Tris-HCl pH 7.1 at 4 °C with 2 × 4 mL filter washes was found to be optimal for specific binding to GluK1. There was no pH dependency of the binding between pH 7.1 and 7.8. Binding of [\(\text{[H]}\)]-NF608 to native GluK1 in rat brain P2 membranes was tested using the high affinity GluK1-selective ligand 10 μM UBP310 to evaluate nonspecific binding and, although a small amount of specific binding was detected, it was insufficient to perform pharmacological analyses at native GluK1. This is likely due to the low specific activity of the radioligand (16.3 Ci mmol\(^{-1}\)).

\subsection*{Kinetics}

The association and dissociation kinetics of [\(\text{[H]}\)]-NF608 binding were examined at GluK1 at 4 °C (Fig. 3). The association
rate was measured as \((mean \pm SEM) k_{on} = 10.05 \pm 1.30 \times 10^6 \text{ min}^{-1} \text{nM}^{-1} (n = 3)\) and the dissociation rate determined as \((mean \pm SEM) k_{off} = 0.0274 \pm 0.0017 \text{ min}^{-1} (n = 4)\). The time course of binding at 4 °C indicated that equilibrium is attained by 1 h. Calculation of the affinity from the kinetic rate constants gave a kinetic \(K_d\) (mean \pm SEM) \(= 2.72 \pm 0.39\) nM, which agrees well with the previously determined affinity of NF608 at GluK1 \((K_i = 5.29 \pm 0.66\) nM).\(^7\)

**Saturation**

The equilibrium binding affinity of \(^{3}H\)-NF608 at GluK1 was measured in saturation binding (Fig. 4) where \((mean \pm SEM, n = 3) K_d = 6.68 \pm 0.88\) nM, \(B_{max} = 5829 \pm 248 \text{ fmol mg}^{-1} \text{ protein}.\) This affinity is not statistically significantly different \((p = 0.251, t\)-test\) from our previously determined affinity of NF608 at GluK1 using \(^{3}H\)SYM2081 as the radioligand.

**Competition**

The pharmacological profile of a selected series of KA receptor ligands was examined using \(^{3}H\)-NF608 (Fig. 5). A comparison of the profile to that previously observed using \(^{3}H\) SYM2081 as the radioligand\(^7\) shows reasonable agreement and Hill values are near unity for all ligands tested (Table 2). Analysis of homologous competition binding with NF608 yielded a \(K_d = 6.93\) nM \((pK_d = 8.160 \pm 0.047)\) (Fig. 6), which is identical to the \(K_d\) determined from saturation analysis.

**Conclusion**

In conclusion we have reported a short and efficient method for the radiosynthesis of the selective GluK1 radioligand \(^{3}H\)-NF608. The radioligand was characterized in in vitro binding assays at cloned homomeric GluK1 receptors and binding affinities \((K_i)\) of a series of standard GluK1 ligands were shown to be in line with previously reported affinities obtained by use of already reported radioligands.

**Experimental section**

**Chemistry**

All reactions involving dry solvents or sensitive agents were performed under a nitrogen or argon atmosphere, and glassware was dried prior to use. Commercially available chemicals were used without further purification. Solvents were dried prior to use with an SG water solvent purification system or dried by standard methods. Reactions were monitored by analytical thin-layer chromatography (TLC, Merck silica gel 60 F254 aluminum sheets), analytical HPLC or UPLC. Flash chromatography was carried out using the Merck silica gel 60 (15–40 μm) or Merck silica gel 60 (40–63 μm). \(^1H\) NMR spectra were recorded on a 400 MHz Bruker Avance III or 600 MHz Bruker Avance III HD, and \(^13C\) NMR spectra on a 101 MHz Bruker Avance III or 151 MHz Bruker Avance III HD. Chemical shifts are reported in \(\delta\) (ppm) relative to the singlet at \(\delta = 7.26\) ppm of CDCl\(_3\), the quintet at 2.50 ppm of DMSO-d\(_6\), and the singlet at 4.79 ppm of D\(_2\)O for \(^1H\) NMR, and to the centre line of the triplet at \(\delta = 77.16\) ppm of CDCl\(_3\), the heptuplet at 39.52 ppm of DMSO-d\(_6\) for \(^13C\)-NMR. Analytical HPLC was performed using a Dionex Ultimate 3000 pump and Dionex Ultimate 3000 Diode Array Detector (200, 210, 225 and 254 nm) installed with a Phenomenex Gemini-NX 3μ C18 110A, 250 × 4.60 mm column.
Solvent A: H$_2$O + 0.1% TFA; solvent B: MeCN–H$_2$O 9 : 1 + 0.1% TFA. For HPLC control, data collection and data handling, Chromeleon software v. 6.80 was used. Preparative HPLC was carried out on an Ultimate 3000 Thermo SCIEN- TIFIC system with a Dionex Ultimate 3000 series pump, a Dionex Ultimate 3000 Diode Array Detector (200, 210, 225 and 254 nm), and a Phenomenex Gemini-NX 5μ C18 110A, 250 × 21.20 mm column for preparative purifications or a Phenomenex Gemini-NX 5μ C18 110A, 250 × 10.00 mm column for semi-preparative purifications. Solvent A: H$_2$O + 0.1% TFA; solvent B: MeCN–H$_2$O 9 : 1 + 0.1% TFA. For HPLC control, data collection and data handling, Chromeleon software v. 6.80 was used. UPLC-MS spectra were recorded using an Acquity UPLC H-Class Waters series solvent delivery system equipped with an autoinjector coupled to an Acquity QDa and TUV detectors installed with an Acquity UPLC®BECH C18 1.7 μm column. Solvent A: 5% aq HCO$_2$H + 0.1% HCO$_2$H; solvent B: MeCN + 0.1% HCO$_2$H. Usually, gradients from A : B 1 : 0 to 0 : 1 (5 min) or A : B 1 : 0 to 0 : 50 (5
min), were performed depending on the polarity of the compounds. For data collection and data handling, MassLynx software was used. Compounds were dried under high vacuum or freeze dried using a ScanVac Cool Safe Freeze Drier. The purity of compounds submitted for pharmacological characterization was determined by $^1$H-NMR and HPLC to be >95%.

Table 1  Binding assay conditions evaluated

<table>
<thead>
<tr>
<th>Buffers (50 mM)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris-HCl</td>
<td></td>
</tr>
<tr>
<td>Tris-HCl + 100 mM NaCl</td>
<td></td>
</tr>
<tr>
<td>Bis-Tris-HCl</td>
<td></td>
</tr>
<tr>
<td>Na’HEPES</td>
<td></td>
</tr>
<tr>
<td>Na’MOPS</td>
<td></td>
</tr>
<tr>
<td>Na’TES</td>
<td></td>
</tr>
<tr>
<td>NaH$_2$PO$_4$</td>
<td></td>
</tr>
<tr>
<td>Na’PIPES</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td></td>
</tr>
<tr>
<td>7.1</td>
<td></td>
</tr>
<tr>
<td>7.4</td>
<td></td>
</tr>
<tr>
<td>7.6</td>
<td></td>
</tr>
<tr>
<td>7.8</td>
<td></td>
</tr>
<tr>
<td>Temperature (°C)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Filter washing (mL)</td>
<td></td>
</tr>
<tr>
<td>$2 \times 3$</td>
<td></td>
</tr>
<tr>
<td>$3 \times 3$</td>
<td></td>
</tr>
<tr>
<td>$2 \times 4$</td>
<td></td>
</tr>
<tr>
<td>$3 \times 4$</td>
<td></td>
</tr>
<tr>
<td>$2 \times 5$</td>
<td></td>
</tr>
<tr>
<td>$3 \times 5$</td>
<td></td>
</tr>
</tbody>
</table>

Overview of the various assay conditions tested. The pH, temperature and washing conditions were only evaluated using 50 mM Tris-HCl buffer.

For the tritiation experiments

$^1$H-, $^3$H- and $^{13}$C NMR spectra were recorded at 300/320 MHz and 75 MHz, respectively, with a Bruker Avance II 300 MHz instrument at 25 °C. The residual solvent signals in the $^1$H and $^{13}$C NMR spectra were used as an internal reference (CDCl$_3$: $\delta = 7.26$ for $^1$H and $\delta = 77.23$ for $^{13}$C). The mass spectra were obtained by the Bruker Daltonics Esquire 4000 system with a direct input (ESI, stream ACN–H$_2$O, a mass range of 50–1200 Da, Esquire Control Software). The HR-mass spectra were obtained in the ESI mode either on a Waters.

Fig. 3  Association and dissociation kinetic experiments of $[^3$H]-NF608 binding to recombinant, homomeric rat GluK1 expressed in sf9 cell membranes. Dissociation was initiated after a 2 h equilibration with the radioligand. Shown are pooled, normalized data from 3–4 experiments conducted in triplicate. Nonspecific binding was determined in the presence of 1 mM (S)-glutamate.

Fig. 4  Saturation binding of $[^3$H]-NF608 (16.3 Ci mmol$^{-1}$) to recombinant, homomeric rat GluK1 expressed in sf9 cell membranes. Shown are pooled, normalized data from 3 experiments conducted in triplicate. Nonspecific binding was determined in the presence of 1 mM (S)-glutamate. From the pooled analysis: $K_d = 6.61 \pm 0.50$ nM, $B_{max} = 4675 \pm 76$ fmol mg$^{-1}$ protein, $n_H = 1.07 \pm 0.07$.

Fig. 5  Competition binding at recombinant, homomeric rat GluK1 expressed in sf9 cell membranes. Shown are pooled, normalized data from 3 experiments conducted in triplicate. DA, domoic acid; ATPA, (RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid; KA, kainic acid; QA, quisqualic acid; Glu, (S)-glutamic acid; UBP310, (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-thiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione.
Micromass Q-TOF Micro mass spectrometer or on a Thermo Fisher Scientific LTQ Orbitrap XLc. The tritiation reaction was performed on a custom-designed tritium manifold system manufactured by RC Tritic AG, Switzerland. Activities were measured on a Perkin-Elmer TriCarb 2900TR liquid scintillation counter (LSC) in a Zinsser Quicksafe A cocktail. The HPLC was performed on a system consisting of a WATERS Delta 600 Pump and Controller, a WATERS 2487 UV detector and a RAMONA radio chromatographic detector from Raytest (Germany) with interchangeable fluid cells. For the preparative runs, the cell with a single small crystal of solid scintillator was used; for analytical runs, the column effluent was mixed with a Zinsser Quickszint Flow 302 cocktail at the ratio of 1:3.

*tert*-Butyl (S)-(2-oxooxetan-3-yl)carbamate (2). To an iced-cooled solution of triphenylphosphine (95%, 7.3 g, 26.53 mmol) in anhydrous THF (50 mL), was added diethyl azodicarboxylate (DEAD, 97%, 4.6 mL, 28.95 mmol). The resulting mixture was stirred at room temperature overnight. Then, the reaction mixture was cooled again to 0 °C and then sodium hydride (60% w/w in mineral oil, 214 mg, 5.34 mmol) was added. The resulting suspension was stirred 50 minutes at room temperature. After that time, the reaction mixture was cooled again to 0 °C and a solution of tert-butyl (S)-(2-oxooxetan-3-yl)carbamate (2) (1 g, 5.34 mmol) in anhydrous DMF (20 mL) was added. The resulting mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched by adding water dropwise until no reaction was observed. The solvent of the reaction mixture was co-evaporated with toluene (3 × 20 mL) to get a white solid that was divided in 6 portions and each one was dissolved in DMSO-MeCN (15:1, 1 mL) and purified by 6 consecutive preparative HPLC purifications (Rf: 19.53 min; flow: 10 mL min⁻¹; A-B: 1:0 to 25:75 (25 min); A-B: 25:75 (5 min); preferably λ = 254 nm, since DMSO does not absorb) to afford the desired compound 3 as a white solid (206 mg, 11%). Recrystallization from anhydrous DMF (30 mL) afforded 3 as a white solid (206 mg, 11%).

**Table 2** Pharmacological profile of GluK1 ligands at recombinant, homomeric rat GluK1 expressed in sf9 cell membranes

<table>
<thead>
<tr>
<th>Radioligand →</th>
<th>[³H]SYM2081</th>
<th></th>
<th>[³H]NF608</th>
</tr>
</thead>
<tbody>
<tr>
<td>Competitor ↓</td>
<td></td>
<td>[³H]SYM2081</td>
<td>[³H]NF608</td>
</tr>
<tr>
<td>(S)-NF608</td>
<td>5.29 ± 0.66⁺</td>
<td>0.99 ± 0.03</td>
<td>9.9 ± 2.6</td>
</tr>
<tr>
<td>UB310</td>
<td>22.1 ± 4.6⁺</td>
<td>0.78 ± 0.03</td>
<td>44.6 ± 6.6</td>
</tr>
<tr>
<td>(RS)-ATPA</td>
<td>2.13 ± 0.21</td>
<td>0.96 ± 0.03</td>
<td>11.9 ± 4.6</td>
</tr>
<tr>
<td>Kainic acid</td>
<td>76 ± 12⁺</td>
<td>0.99 ± 0.04</td>
<td>135 ± 5</td>
</tr>
<tr>
<td>Quisqualic acid</td>
<td>171 ± 93</td>
<td>0.93 ± 0.03</td>
<td>344 ± 72</td>
</tr>
<tr>
<td>Domoic acid</td>
<td>1.11 ± 0.20⁺</td>
<td>0.99 ± 0.04</td>
<td>6.41 ± 2.48</td>
</tr>
<tr>
<td>(S)-Glutamic acid</td>
<td>140 ± 3⁺</td>
<td>0.98 ± 0.03</td>
<td>292 ± 24</td>
</tr>
</tbody>
</table>

Shown are means ± SEM of at least 3 experiments conducted in triplicate at 12–16 ligand concentrations. Ref. 7. Ref. 15. Ref. 5.

**Fig. 6** Homologous competition binding of [³H]-NF608 vs. NF608 at recombinant, homomeric rat GluK1 expressed in sf9 cell membranes. Shown are means ± SEM of triplicate values normalized for the maximum specific binding in each individual experiment. Non-specific binding is determined using 1 mM (maximal specific binding in each individual experiment). Nonspecific concentrations (nM). Analysis of the pooled data to solve for a common hill value gave (mean ± SEM) Bₐₙₙ = 8.93 nM (pKₐ = 8.160 ± 0.047). Solving for a common hill value gave (mean ± SEM) nₜₜ = 0.9899 ± 0.0455.
Methyl 3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (8); methyl 5-bromo-3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (9). Methyl 3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (8); methyl 5-bromo-3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (9) were synthesized according to ref. 13.

Methyl 5-bromo-3-ureidothiophene-2-carboxylate (10). To an ice-cooled suspension of 9 (7.84 g, 17.55 mmol) in anhydrous MeOH (70 mL), was added 2 M NH₄ solution (in MeOH, 17.5 mL, 35.09 mmol) and this mixture was stirred at room temperature for 30 minutes, during which time a white solid precipitated. After this period, the white solid was filtered and washed with cold MeOH (3 × 10 mL) to give the compound 10 (4.37 g, 89%) as a white solid with a purity of 98% (determined by ¹H-NMR). ¹H NMR (400 MHz, DMSO-d₆) δ 9.23 (s, 1H), 8.06 (s, 1H), 6.86 (br s, 2H), 3.80 (s, 3H). Product described in ref. 13.

6-Bromothieno[3,2-d]pyrimidine-2,4(1H,3H)-dione (11). 6-Bromothieno[3,2-d]pyrimidine-2,4(1H,3H)-dione (11) (581 mg, 2.35 mmol) in anhydrous DMF (11.4 mL) was cooled to 0 °C and then sodium hydride (60% w/w in mineral oil, 85 mg, 2.14 mmol) was added. The resulting suspension was stirred for 40 minutes at room temperature. After that time, the reaction mixture was cooled again to 0 °C and a solution of tert-butyl (S)-(2-oxooxetan-3-yl)carbamate (2) (400 mg, 2.14 mmol) in anhydrous DMF (10 mL) was added. The resulting mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched by adding water dropwise until no reaction was observed. The solvent of the reaction mixture was co-evaporated with toluene (3 × 10 mL) to get a white solid that was divided into 7 portions and each one was dissolved in DMSO-DMF (15:1, 1.5 mL) and purified by 7 consecutive preparative HPLC purifications (Rt: 28.60 min; flow: 10 mL min⁻¹; A (10 min), A-B 75: 25 to 25:75 (25 min), preferably λ = 254 nm because DMSO do not absorbs) to afford the desired compound as a white solid (187 mg, 18%). ¹H NMR (600 MHz, DMSO-d₆) δ 13.06 (br s, 1H), 11.64 (s, 1H), 7.57 (s, 1H), 7.04 (d, J = 8.9 Hz, 1H), 4.44-4.37 (m, 2H), 3.95 (dd, J = 15.2, 11.0 Hz, 1H), 1.21 (s, 9H). ¹³C NMR (151 MHz, DMSO-d₆) δ 170.9, 157.2, 155.1, 150.9, 147.5, 122.4, 122.1, 112.9, 78.2, 51.1, 46.8, 27.8. UPLC-MS (m/z) calcd for C₉H₉BrN₃O₄S [M + H⁺], 333.9; found, 333.9.

(S)-2-(6-Bromo-2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)-1-carboxyethan-1-aminium chloride (13). A suspension of (S)-2-(6-Bromo-2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)-1-(tert-butoxy carbonylamino)propanoic acid (12) (122 mg, 0.28 mmol) in 2 M aq HCl (6 mL), was heated to 50 °C during 1 hour. After that time, the solvent and volatiles were removed under reduced pressure to afford the title compound as a white solid (98 mg, 94%), which was used in next reaction step without further purification. ¹H NMR (600 MHz, DMSO-d₆) δ 11.73 (s, 1H), 8.40 (s, 3H), 7.68 (s, 1H), 4.44 (dd, J = 15.0, 6.3 Hz, 1H), 4.27 (dd, J = 15.0, 7.9 Hz, 1H), 4.10 (br t, J = 6.3 Hz, 1H). ¹³C NMR (151 MHz, DMSO-d₆) δ 168.3, 157.2, 151.4, 146.6, 123.0, 121.6, 113.5, 50.5, 44.7. UPLC-MS (m/z) calcd for C₂H₈BrN₂O₄S[M + H⁺], 333.9; found, 333.9.

Sodium (S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide-6-d ([DG]-NF608 disodium salt) and sodium (S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide (NF608 disodium salt). Pd/C (1.8 mg, 10% Pd on activated C, water-wet) was weighed in a small flask that was repeatedly filled and evacuated with N₂ (3 times), and then D₂ (3 times). In parallel, (S)-2-(6-bromo-2,4-dioxo-3,4-dihydrothieno[3,2-d]-pyrimidin-1(2H)-yl)-1-carboxyethan-1-aminium chloride (13) (9 mg, 0.024 mmol) was weighed in a separate flask that was repeatedly filled and evacuated with N₂ (3 times). Then, water (240 μL) and 1 M aq NaOH (69 μL, 0.069 mmol) were added to afford a suspension that was heated to 60 °C for 5 minutes until getting a clear solution that was transferred to the previous flask with Pd/C. The resulting mixture was repeatedly filled and evacuated with D₂ (3 times), and stirred vigorously at room temperature overnight under D₂ (1 atm). After this period, the reaction mixture was filtered through a plug of Celite®, and the filtrate was washed with water (3 × 3 mL). Then, the filtrate was concentrated in vacuo to give the deuterated:hydrogenated disodium salts of products [DG]-NF608:NF608 in a 4:1 ratio, as a white solid (4 mg, 57%, 80% D-incorporation).

Sodium (S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide (NF608). ¹H NMR (600 MHz, D₂O) δ 7.29 (br s, 1H), 4.29 (dd, J = 7.1 Hz, 2H), 3.75 (t, J = 7.1 Hz, 1H). ¹³C NMR (151 MHz, D₂O) δ 178.6, 163.6, 155.3, 148.5, 136.3, 117.1, 113.3, 54.8, 49.0. UPLC-MS (m/z) calcd for C₂H₈DN₂O₄S[M + H⁺], 257.0; found, 257.0.

Sodium (S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide (NF608). ¹H NMR (600 MHz, D₂O) δ 8.02 (dd, J = 5.5 Hz, 1H), 7.29 (dd, J = 5.5 Hz, 1H), 4.29 (dd, J = 7.1 Hz, 2H), 3.75 (t, J = 7.1 Hz, 1H). ¹³C NMR (151 MHz, D₂O) δ 178.6, 163.6, 155.3, 148.5, 136.3, 117.2, 113.3, 54.8, 49.0.

(S)-2-(6-Bromo-2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)-1-(2-amino-2-carboxylatoethyl)pyrimidin-1(2H)-yl)carbamate (98%) as a white solid (4.37 g, 89%) as a white solid with a purity of 98% (determined by ¹H-NMR). ¹H NMR (400 MHz, DMSO-d₆) δ 9.23 (s, 1H), 8.06 (s, 1H), 6.86 (br s, 2H), 3.80 (s, 3H). Product described in ref. 13.
were rinsed with H₂O (3 × 0.6 mL). To remove labile activity, the solvent with addition of EtOH (2 mL) was repeatedly lyophilized (3 × 3 mL H₂O/EtOH 50:50). The activity of crude product (63% R.C.P.) was determined at 65 mCi. The crude product was dissolved in H₂O (1 mL) and purified by radio-HPLC on a Syngeri 4 μ POLAR RP80A 250 × 4.6 mm semipreparative column using gradient elution with A = water, B = acetonitrile (flow of 4.7 mL min⁻¹, 25 °C, 100% of A for 25 min, 100% of B in 35 min). The retention time of [³H]-NF608 was detected at 19.3 min. Pure [³H]-NF608 was isolated in total activity 23.5 mCi (16.3 Ci mmol⁻¹), 23% R.C.Y. The specific activity was determined by HRMS at 16.3 Ci mmol⁻¹. [³H]-NMR (320 MHz, D₂O): δ 8.08 (1 T, s). HRMS (ESI): calc. for C₄H₇N₃O₄S⁻ M - 1 256.0318; found 256.0319.

Pharmacology

Recombinant homomeric rat GluK1(Q)₁₂b, GluK2(V,C,R)₄a and GluK3₃a were expressed in sf9 insect cells as previously described.⁵ Rat whole brain (mixed sex) crude synaptosomal (P2) membranes were prepared by standard methods.¹⁴ For use in binding assays, an aliquot of membranes was thawed and washed four times by centrifugation 48 000 × g, 15 min at 4 °C with Ultra-Turrax resuspension in 25 mL ice-cold hypotonic buffer (5 mM Tris-HCl, pH 7.4, 4 °C). Membranes were then resuspended in assay buffer (50 mM Tris-HCl, pH 7.1, 4 °C). Binding assays were conducted in a volume of 250 μL at 4 °C and kinetic and saturation assays terminated by rapid filtration through 0.3% (w/v) polyethyleneimine-treated GF/C-type glass fiber filters (VWR filter #696; VWR, Denmark) on 12-well Millipore filtration manifolds (Millipore, Darmstadt, Germany), washing twice with 4 mL ice-cold assay buffer. Filters were equilibrated in 3 mL EcoScint scintillation fluid (National Diagnostics, Atlanta, GA) for 12 h and radioactivity detected as DPM using a Tri Carb 2900 scintillation counter (PerkinElmer, Waltham, MA). Non-specific binding was determined in the presence of 1 mM (S)-glutamate. In competition experiments, bound and free radioligand were separated by cold filtration through GF/B glass fiber filters in UniFilter-96 microtitre plates (PerkinElmer) on a FilterMate manifold (PerkinElmer) using two washes with ice-cold assay buffer. Filters were dried 1 hour at 70 °C and 50 μL Microscint 20 (PerkinElmer) was added. Radioactivity was detected as DPM using a TopCounter (PerkinElmer).

Binding data were analyzed with GraphPad Prism v6 (GraphPad Software, San Diego, CA) using: one-site Kᵢ and four-parameter logistic equations for competition data, one site-homologous equation for [³H]kainate Kᵢ₄ determination, mono-exponential rate equations for association and dissociation data and one-site total and nonspecific binding for [³H]-NF608 saturation binding.

Abbreviations

KA Kainic acid
Glu (S)-Glutamic acid
DA Domoic acid

QA Quisqualic acid
NF608 (S)-2-Amino-3-(2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)propanoic acid
ATPA (RS)-2-Amino-3-(3-hydroxy-5-tert-butyloxazol-4-yl)propanoic acid
UBP310 (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxythiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione

Acknowledgements

The authors thank the Department of Drug Design and Pharmacology and the Academy of Sciences of the Czech Republic (program RVO: 61388963) for the financial support.

References


